Connect Biopharma (CNTB) completed the termination of the Deposit Agreement dated March 18, 2021, as amended, among the Company, Deutsche Bank Trust Company Americas, and the holders and beneficial owners of American Depositary Shares evidenced by American Depositary Receipts issued thereunder and that the Company’s ordinary shares are now directly listed on the Nasdaq Global Market. The ADR program and the Deposit Agreement terminated on September 2, 2025. At such time, the Company’s ADRs were mandatorily cancelled and exchanged for ordinary shares at a one-for-one ratio. The Company’s ordinary shares commence trading directly on Nasdaq today under the Company’s existing symbol “CNTB”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTB:
- Connect Biopharma Advances Clinical Trials and Nasdaq Listing
- Connect Biopharma patners with Ickey Woods, Jovante Woods Foundation
- Promising Developments and Strategic Moves Justify Buy Rating for Connect Biopharma Holdings
- Connect Biopharma reports Q2 EPS (23c) vs. 27c last year
- Connect Biopharma sees cash runway into 2027